%0 Journal Article
%T MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines
%A H. Y. Lim
%A J. E. Kim
%A J. Lee
%A J. O. Park
%A K.K. Kim
%A S. H. Park
%A S. T. Kim
%A S. Y. Kim
%A W. K. Kang
%A Y. S. Park
%J Journal of Cancer
%D 2017
%I Ivyspring International Publisher
%R 10.7150/jca.19582
%X BACKGROUND: The MAP2K1 K57T mutation is known to be a potential mechanism of primary and secondary resistance to EGFR inhibitors in metastatic colorectal cancer (CRC) and has also been reported to promote resistance to BRAF and MEK inhibitors. It is important to overcome therapeutic resistance to EGFR inhibitors to improve the treatment outcomes of metastatic CRC.
%K MAP2K1 mutation
%K MEK inhibitor
%K RAF inhibitor
%U http://www.jcancer.org/v08p2263.htm